Retatrutide
PopularTriple GIP/GLP-1/glucagon agonist
Research use only Third-party tested
Research context
Human phase 2 data exist and phase 3 studies are ongoing, but retatrutide is investigational and not an FDA-approved product.
- Substantial weight-loss claims in obesity trial discussions.
- Interest in cardiometabolic markers, liver-fat reduction, and appetite regulation.
- Often compared online with tirzepatide and semaglutide, though it is not approved.
Evidence snapshot
See full evidence tabLast updated: June 2025
Mechanism of action
Targets GIP, GLP-1, and glucagon receptors.
Learn more about mechanismQuick facts
- Aliases
- LY3437943
- Molecular weight
- TBD
- Sequence length
- TBD
- Product type
- Synthetic
- CAS / Registry
- TBD
- Appearance
- White lyophilized powder
- Solubility
- Water
Safety notes
For research use only. Not for human or veterinary use.
- Common research observations: nausea, reduced appetite, GI discomfort
- Monitor hydration and nutrient intake in long-term studies
- Consult current literature for full safety profile and contraindications
Popular research protocols
View all protocolsResearch use onlyAll peptides are intended for laboratory research purposes only. Not for human or veterinary use.